Literature DB >> 15728544

Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat.

Michael Blair1, Mary Ellen Pease, John Hammond, Danielle Valenta, Jennifer Kielczewski, Hana Levkovitch-Verbin, Harry Quigley.   

Abstract

PURPOSE: After crush injury to the optic nerve, elevated intraocular pressure, and glutamate toxicity, the immune modulator glatiramer acetate (GA, Cop-1; Copaxone; Teva Pharmaceutical Industries, Pitach Tikva, Israel) has been shown to reduce the delayed cell death of retinal ganglion cells (RGCs). This study was undertaken to confirm the protective effect of GA on secondary degeneration of RGCs in the rat, by using a spatial, rather than temporal, model.
METHODS: A total of 131 Wistar rats divided into 10 groups underwent bilateral stereotactic injection of fluorescent tracer (Fluorogold; Fluorochrome, Denver, CO) into the superior colliculus to label RGCs. They received a concurrent subcutaneously injection of (1) GA mixed with complete Freund's adjuvant (CFA), (2) CFA alone, or (3) saline. One week later, the superior one third of the left optic nerve was transected in animals in the six partial transection groups. Optic nerves in four additional groups underwent full transection. Rats were killed and retinas harvested from both eyes 1 or 4 weeks after partial transection and 1 or 2 weeks after full transection. RGC densities were calculated from retinal wholemounts, and differences between right (control) and left (transected) eyes were compared across treatment groups.
RESULTS: Among the partial transection groups, differences in the mean percentage of RGC loss in the inferior retinas were not significant at 1 or 4 weeks (ANOVA; P = 0.20, P = 0.12, respectively). After full transection, there was significantly more RGC loss in the GA group than in the CFA group when comparing whole retinas at 1 week, but not at 2 weeks (two-tailed t-test; P = 0.04, P = 0.36, respectively).
CONCLUSIONS: There is no evidence that GA has a neuroprotective effect after optic nerve transection, either for primarily injured or secondarily involved RGC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728544     DOI: 10.1167/iovs.04-0731

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  Lack of neuroprotection against experimental glaucoma in c-Jun N-terminal kinase 3 knockout mice.

Authors:  Harry A Quigley; Frances E Cone; Scott E Gelman; Zhiyong Yang; Janice L Son; Ericka N Oglesby; Mary E Pease; Donald J Zack
Journal:  Exp Eye Res       Date:  2011-01-25       Impact factor: 3.467

2.  Neuroprotective effects of BDNF and GDNF in intravitreally transplanted mesenchymal stem cells after optic nerve crush in mice.

Authors:  Zong-Li Hu; Ni Li; Xin Wei; Li Tang; Ting-Hua Wang; Xiao-Ming Chen
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

3.  Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection.

Authors:  Frances E Cone; Scott E Gelman; Janice L Son; Mary E Pease; Harry A Quigley
Journal:  Exp Eye Res       Date:  2010-06-26       Impact factor: 3.467

4.  Involvement of the CD200 receptor complex in microglia activation in experimental glaucoma.

Authors:  Sarah Taylor; Claudia J Calder; Julie Albon; Jonathan T Erichsen; Micheal E Boulton; James E Morgan
Journal:  Exp Eye Res       Date:  2011-02-04       Impact factor: 3.467

5.  Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma.

Authors:  Wei Huang; John B Fileta; Adam Dobberfuhl; Theodoros Filippopolous; Yan Guo; Gina Kwon; Cynthia L Grosskreutz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

6.  Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.

Authors:  Antonietta Gentile; Silvia Rossi; Valeria Studer; Caterina Motta; Valentina De Chiara; Alessandra Musella; Helena Sepman; Diego Fresegna; Gabriele Musumeci; Giorgio Grasselli; Nabila Haji; Sagit Weiss; Liat Hayardeny; Georgia Mandolesi; Diego Centonze
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-31       Impact factor: 4.147

Review 7.  Rodent models of glaucoma.

Authors:  Thomas V Johnson; Stanislav I Tomarev
Journal:  Brain Res Bull       Date:  2009-04-18       Impact factor: 4.077

Review 8.  Solving the lost in translation problem: improving the effectiveness of translational research.

Authors:  Ceren Ergorul; Leonard A Levin
Journal:  Curr Opin Pharmacol       Date:  2012-09-11       Impact factor: 5.547

9.  RNA binding protein with multiple splicing: a new marker for retinal ganglion cells.

Authors:  Jacky M K Kwong; Joseph Caprioli; Natik Piri
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-09-08       Impact factor: 4.799

10.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.